FDA report doubts need for Advair approval at higher doses

04/28/2007 | MarketWatch · Wall Street Journal, The

An FDA report in advance of a Tuesday advisory committee meeting casts doubt on whether higher doses of Advair should be approved to treat patients with chronic obstructive pulmonary disease to increase survival and reduce exacerbations. GlaxoSmithKline's Advair already is approved as an asthma treatment and to treat COPD patients at 250/50 microgram doses, but GSK wants clearance at 500/50 microgram doses.

View Full Article in:

MarketWatch · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC